| GABGX | RGACX | GABGX / RGACX | |
| Total Expense Ratio | 1.33 | 0.93 | 143% |
| Annual Report Gross Expense Ratio | 1.33 | 0.93 | 143% |
| Fund Existence | 39 years | 24 years | - |
| Gain YTD | 4.991 | 9.283 | 54% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000 | 250 | 400% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 1.33B | 353B | 0% |
| Annual Yield % from dividends | 0.00 | 0.00 | - |
| Returns for 1 year | 2.04 | 0.87 | 234% |
| Returns for 3 years | 61.06 | 41.63 | 147% |
| Returns for 5 years | 29.92 | 11.29 | 265% |
| Returns for 10 years | 173.06 | 101.73 | 170% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RYCFX | 53.90 | N/A | N/A |
| Rydex Biotechnology C | |||
| FDTCX | 37.28 | N/A | N/A |
| Fidelity Advisor Diversified Stock C | |||
| VLACX | 142.54 | N/A | N/A |
| Vanguard MStar Large Cap Index Investor | |||
| CRIHX | 13.29 | N/A | N/A |
| CRM Long/Short Opportunities Instl | |||
| AVEEX | 18.29 | -0.06 | -0.33% |
| Avantis® Emerging Markets Equity Instl | |||